Group 1 - The core viewpoint of the news is that Ruizhi Pharmaceutical experienced a decline in stock price and significant changes in financing activities on October 23, with a net financing outflow of 457.09 million yuan [1] - As of October 23, the total financing and securities balance for Ruizhi Pharmaceutical was 1.91 billion yuan, which represents 3.39% of its circulating market value, indicating a high level of financing [1] - The company reported a financing buy-in of 7.96 million yuan and a financing repayment of 12.53 million yuan on the same day, reflecting a negative net financing activity [1] Group 2 - As of October 20, the number of shareholders for Ruizhi Pharmaceutical was 42,500, a slight decrease of 0.10%, while the average circulating shares per person increased by 0.10% to 11,161 shares [2] - For the first half of 2025, Ruizhi Pharmaceutical achieved an operating income of 534 million yuan, representing a year-on-year growth of 14.75%, and a net profit attributable to the parent company of 25.38 million yuan, which is a significant increase of 140.35% year-on-year [2] - Since its A-share listing, Ruizhi Pharmaceutical has distributed a total of 180 million yuan in dividends, with no dividends paid in the last three years [3]

Core Insights - As of October 20, 2025, the number of shareholders for Ruizhi Pharmaceutical (300149) is projected to be 42,517 households [1] Company Summary - The company has provided an update regarding its shareholder count, indicating a specific target date for this information [1]

Group 1 - The CRO concept index rose by 2.56%, ranking 10th among concept sectors, with 64 stocks increasing in value, led by Hanyu Pharmaceutical, Boteng Co., and Meidi Xi, which rose by 7.87%, 6.85%, and 6.28% respectively [1][2] - The top three stocks in terms of net inflow of main funds were Hanyu Pharmaceutical with a net inflow of 172 million yuan, followed by Fosun Pharma and Huace Testing with net inflows of 40.96 million yuan and 36.48 million yuan respectively [2][3] Group 2 - The main fund inflow rates for stocks such as Ruizhi Pharmaceutical, Hanyu Pharmaceutical, and Jiannang Technology were 10.21%, 10.19%, and 8.41% respectively, indicating strong investor interest [3] - The CRO concept sector saw a net inflow of 322 million yuan today, with 45 stocks experiencing net inflows, and five stocks exceeding 30 million yuan in net inflow [2][3] Group 3 - The stocks with the highest trading turnover in the CRO concept included Hanyu Pharmaceutical with a turnover rate of 10.59%, followed by Fosun Pharma at 0.88% and Huace Testing at 5.74% [3][4] - The overall performance of the CRO concept was positive, with several stocks showing significant gains, while a few, such as Inno Laser and ST Weiming, experienced declines of 3.16% and 1.74% respectively [1][5]

Core Viewpoint - Ruizhi Pharmaceutical has received an inquiry letter from the Shenzhen Stock Exchange regarding its application for a private placement of shares, indicating ongoing regulatory scrutiny and the need for further approvals before proceeding with the issuance [1]. Group 1: Company Actions - The company, along with relevant intermediaries, has carefully studied the issues raised in the inquiry letter and has provided responses, updating the prospectus and other application documents, which were disclosed on October 13 [1]. - The issuance of shares is contingent upon approval from the Shenzhen Stock Exchange and registration consent from the China Securities Regulatory Commission, highlighting the regulatory hurdles the company faces [1]. Group 2: Regulatory Environment - The final decision on whether the application will be approved and the timeline for such decisions remain uncertain, indicating potential delays in the company's fundraising efforts [1]. - The company has committed to timely information disclosure based on the progress of the application, emphasizing its obligation to keep investors informed about developments [1].

Core Viewpoint - The company has responded to the Shenzhen Stock Exchange's inquiry regarding its application for a specific stock issuance, with the auditing firm conducting a thorough review of related issues [1] Performance Fluctuation Reasons and Improvement Measures - The company reported revenues of 1,326.58 million, 1,138.37 million, 970.20 million, and 533.80 million, with gross profit margins of 25.42%, 25.94%, 21.80%, and 29.01%, and net profits of 362.42 million, -916.94 million, -226.51 million, and 25.35 million over the reporting periods [2] - Revenue and gross margin have declined due to competition in the innovative drug industry, but began to recover in the first half of 2025 [2] - Net profit fluctuations were influenced by business adjustments and goodwill impairments [2] Business Segment Analysis - The chemical business faced reductions due to market competition and shifts in client R&D directions [2] - The large molecule business struggled with order acquisition but saw revenue growth in the first half of 2025 as the market improved [2] - The pharmacodynamics business experienced revenue growth in 2023 due to platform expansion but fell short of expectations in 2024, with recovery in 2025 [2] Measures for Performance Improvement - The company benefits from an improved external industry environment, with increased order volumes and active investment [3] - Internal optimizations include governance improvements, business model enhancements, and refined cost management [3] - Goodwill and long-term asset impairments have been addressed, leading to stable future performance expectations [3] Domestic and International Business Performance - The company’s international business primarily serves U.S. clients, with over 70% revenue share [4] - Gross margins for international business have increased due to a higher proportion of high-margin pharmacodynamics business [4] - R&D expenses have decreased as the company adjusts its strategy to focus on core projects [4] Accounts Receivable and Debt Servicing - The company has made adequate provisions for bad debts, with a decline in accounts receivable aging due to reduced revenue and improved management [5] - Liquidity ratios are below industry averages, but the company maintains stable cash reserves for debt servicing [5] - Inventory provisions are higher than industry peers due to strategic focus and insufficient CDMO orders [5] Related Transactions and Asset Impairment - Related transactions are deemed necessary and fair, with no significant financial mismanagement [6] - Fixed asset depreciation policies align with industry norms, and asset impairment provisions are considered reasonable [7] - The company’s management stability and experience are expected to support business development [7]

关于睿智医药科技股份有限公司 向特定对象发行股票的审核问询函回复说明 信会师函字[2025]第 ZI589 号 关于睿智医药科技股份有限公司申请 向特定对象发行股票的审核问询函回复说明 信会师函字[2025]第 ZI589 号 深圳证券交易所： 贵所于 2025 年 09 月 16 日下达的《关于睿智医药科技股份有限 公司申请向特定对象发行股票的审核问询函》（审核函〔2025〕020051 号）（以下简称问询函）已收悉。立信会计师事务所(特殊普通合伙)(以 下简称"会计师"或"本所")作为睿智医药科技股份有限公司(以下简 称"睿智医药"或"公司")申请向特定对象发行股票的审计机构，对问 询函中提到的要求会计师核查的问题进行了审慎核查，现回复如下： 说明： 1、如无特别说明，本问询回复中所涉及的简称或释义与《募集说明书》中相同。 2、本问询函问题的回复中若出现总计数尾数与所列数值总和尾数不符的情况，均为四 舍五入所致。 3、本所没有接受委托审计或审阅 2025 年 1 月至 6 月期间的财务报表，以下所述的核查 程序及实施核查程序的结果仅为协助睿智医药回复贵所问询函目的，不构成审计或审阅。 2-1 问题一 根据 ...

证券简称：睿智医药 证券代码：300149.SZ 关于睿智医药科技股份有限公司 申请向特定对象发行股票的审核问询函 之回复报告 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 二〇二五年十月 深圳证券交易所： 贵所《关于睿智医药科技股份有限公司申请向特定对象发行股票的审核问询 函》（审核函〔2025〕020051 号）（以下简称"问询函"）已收悉。睿智医药 科技股份有限公司（以下简称"睿智医药"、"发行人"或"公司"）会同中信 证券股份有限公司（以下简称"保荐人"）、北京市竞天公诚律师事务所和立信 会计师事务所（特殊普通合伙）就问询函所提问题进行了逐项落实并回复，同时 按照要求对《睿智医药科技股份有限公司 2024 年度向特定对象发行股票募集说 明书》（以下简称"募集说明书"）进行了修订和补充，现回复如下，请贵所予 以审核。 说明： 一、如无特别说明，本回复报告中的简称与募集说明书中的简称具有相同的 含义。 | 黑体： | 问询函所列问题 | | --- | --- | | 宋体： | 对问询函所列问题的回复 | | 楷体： | 对募集说明书的引用 | | 楷体加粗： | 对募 ...

中信证券股份有限公司 关于 睿智医药科技股份有限公司 2024 年度向特定对象发行股票 之 上市保荐书 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 2025 年 10 月 睿智医药科技股份有限公司 上市保荐书 声 明 中信证券股份有限公司（以下简称"中信证券"、"保荐人"或"本保荐 人"）及其保荐代表人周游、王栋根据《中华人民共和国公司法》（下称《公司 法》"）、《中华人民共和国证券法》（下称"《证券法》"）、《上市公司证 券发行注册管理办法》（以下简称"《注册管理办法》"）《证券发行上市保荐 业务管理办法》（以下简称"《保荐管理办法》"）等有关法律、法规和中国证 券监督管理委员会（以下简称"中国证监会"）的有关规定以及深圳证券交易所 （以下简称"深交所"）的有关业务规则，诚实守信，勤勉尽责，严格按照依法 制定的业务规则和行业自律规范出具本上市保荐书，并保证上市保荐书的真实、 准确、完整。 如无特别说明，本上市保荐书中所涉简称与《睿智医药科技股份有限公司 2024 年度向特定对象发行股票募集说明书》一致。 3-3-1 | 声 | 明 1 | | --- | --- | | ...

证券代码：300149 证券简称：睿智医药 睿智医药科技股份有限公司 （ChemPartner PharmaTech Co.,Ltd.） （广东省江门市江海区胜利南路 164 号） 2024 年度向特定对象发行股票 募集说明书 （申报稿） 保荐人（主承销商） 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 二〇二五年十月 声 明 本公司及全体董事、高级管理人员承诺本募集说明书内容真实、准确、完整， 不存在虚假记载、误导性陈述或重大遗漏，按照诚信原则履行承诺，并承担相应 的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人保证募集说明书中财务 会计资料真实、完整。 中国证监会、交易所对本次发行所作的任何决定或意见，均不表明其对申请 文件及所披露信息的真实性、准确性、完整性作出保证，也不表明其对发行人的 盈利能力、投资价值或者对投资者的收益作出实质性判断或保证。任何与之相反 的声明均属虚假不实陈述。 根据《证券法》的规定，证券依法发行后，发行人经营与收益的变化，由发 行人自行负责，投资者自主判断发行人的投资价值，自主作出投资决策，自行承 担证券依法发行后因发行人经营与收益变化或者证券价格变动引 ...

发行保荐书 保荐人（主承销商） 关于 睿智医药科技股份有限公司 2024 年度向特定对象发行股票 之 中信证券股份有限公司 广东省深圳市福田区中心三路 8 号卓越时代广场（二期）北座 声明 本保荐人及保荐代表人根据《中华人民共和国公司法》、《中华人民共和国 证券法》、《上市公司证券发行注册管理办法》、《证券发行上市保荐业务管理 办法》等有关法律、行政法规和中国证券监督管理委员会及深圳证券交易所的规 定，诚实守信，勤勉尽责，严格按照依法制订的业务规则、行业执业规范和道德 准则出具本发行保荐书，并保证所出具文件的真实性、准确性和完整性。 3-1-1 2025 年 10 月 睿智医药科技股份有限公司 2024 年度向特定对象发行股票之发行保荐书 睿智医药科技股份有限公司 2024 年度向特定对象发行股票之发行保荐书 释义 本发行保荐书中，除非文义另有所指，下列简称和术语具有如下含义： 一、普通术语 | 睿智医药、本公司、公司、 | 指 | 睿智医药科技股份有限公司 | | --- | --- | --- | | 发行人 | | | | 本次向特定对象发行/本 次发行 | 指 | 睿智医药科技股份有限公司本次向特定对 ...